The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $5.44

Today's change+0.18 +3.42%
Updated April 29 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $5.44

Today's change+0.18 +3.42%
Updated April 29 4:00 PM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc up sharply

Keryx Biopharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$0.18 or 3.42% to (U.S.)$5.44. Over the last five days, shares have gained 5.63% and 7.72% year to date. Shares have underperformed the S&P 500 by 47.00% during the last year.

Key company metrics

  • Open(U.S.) $5.17
  • Previous close(U.S.) $5.26
  • High(U.S.) $5.69
  • Low(U.S.) $5.17
  • Bid / Ask(U.S.) $5.30 / (U.S.) $6.45
  • YTD % change+7.72%
  • Volume1,681,408
  • Average volume (10-day)1,591,903
  • Average volume (1-month)2,016,550
  • Average volume (3-month)1,845,308
  • 52-week range(U.S.) $2.80 to (U.S.) $11.32
  • Beta4.06
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.18
Updated April 29 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-705.48%

Although this company's net profit margin is negative, it is above the industry average and implies that Keryx Biopharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.47%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue6431
Total other revenue--------
Total revenue6431
Gross profit4121
Total cost of revenue2411
Total operating expense31352929
Selling / general / administrative22202119
Research & development811810
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-25-31-27-28
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-38-31-27-28
Income after tax-38-31-27-28
Income tax, total0000
Net income-38-31-27-28
Total adjustments to net income--------
Net income before extra. items-38-31-27-28
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-38-31-27-28
Inc. avail. to common incl. extra. items-38-31-27-28
Diluted net income-38-31-27-28
Dilution adjustment0------
Diluted weighted average shares105105105101
Diluted EPS excluding extraordinary itemsvalue per share-0.36-0.29-0.26-0.28
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.36-0.29-0.26-0.28